Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jul;23(7):765-767.
doi: 10.1016/S1473-3099(23)00180-9. Epub 2023 Mar 15.

Real-world use of nirmatrelvir-ritonavir: who benefits?

Kyle C Molina  1 , Adit A Ginde  2
Affiliations
Comment

Real-world use of nirmatrelvir-ritonavir: who benefits?

Kyle C Molina et al. Lancet Infect Dis. 2023 Jul.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

KCM reports grants from the US National Center for Advancing Translational Sciences, the National Institute of Child Health and Human Development, and National Heart, Lung, and Blood Institute. AAG reports investigator-initiated grants from the US National Institutes of Health, Centers for Disease Control and Prevention, and Department of Defense, AbbVie, and Faron Pharmaceuticals. He served on a US National Institutes of Health data and safety monitoring board.

Comment on

References

    1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397–1408. - PMC - PubMed
    1. US Centers for Disease Control and Prevention COVID data tracker. 2023. https://covid.cdc.gov/covid-data-tracker
    1. Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00118-4. published online March 15. - DOI - PMC - PubMed
    1. Pfizer Pfizer reports additional data on PAXLOVID supporting upcoming new drug application submission to US. 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-re...
    1. Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00011-7. published online Feb 10. - DOI - PMC - PubMed

Publication types